https://peptidelifestyle360.com/news What regulators actually did, dated and sourced. Peptide and GLP-1 industry news written for people new to the subject. No sellers, no doses, no advice. en Peptide Lifestyle 360 LLC Sat, 14 Nov 2026 12:00:00 GMT 720 https://peptidelifestyle360.com/news#obesityweek-preview-2026-11 obesityweek-preview-2026-11 Sat, 14 Nov 2026 12:00:00 GMT pipeline Novo Nordisk plans to present semaglutide and CagriSema data at ObesityWeek, 14 to 17 November. As of 11 November the meeting has not happened, so there are no conference results to report yet. Novo Nordisk announced planned semaglutide and CagriSema presentations for ObesityWeek in Washington, DC. As of November 11, the meeting is upcoming. Planned presentations should not be described as completed conference results. Source: Novo Nordisk release, 29 October 2026 (Sponsor release). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#survodutide-cvot-2026-11-09 survodutide-cvot-2026-11-09 Mon, 09 Nov 2026 12:00:00 GMT pipeline In a large trial of adults with raised heart risk, the sponsor reports survodutide met its heart-safety goal against placebo. That is a safety result; it does not show the drug prevents heart attacks or strokes. Survodutide is still investigational. Zealand reported that SYNCHRONIZE-CVOT met its primary noninferiority endpoint in 5,530 adults with obesity or overweight and elevated cardiovascular risk. The reported hazard ratio for the primary composite was 0.89, with a 95% confidence interval of 0.67 to 1.18: noninferiority only, with no proven superiority. The release says the full results were published at the same time in The Lancet. Gastrointestinal adverse events and treatment discontinuations remain relevant limitations. Source: Zealand Pharma release, 9 November 2026 (Sponsor release). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#hhs-draft-peptides-2026-10-30 hhs-draft-peptides-2026-10-30 Fri, 30 Oct 2026 12:00:00 GMT regulation HHS published a draft describing when it may not act against certain compounded peptides. A draft is not a final rule and not an approval, and compounded products are not FDA-approved. An HHS notice describes a draft enforcement discretion policy concerning certain peptide compounding under section 503A. A draft policy is not a final rule or FDA approval. Compounded products are not FDA approved. Source: Federal Register / HHS, 30 October 2026 (document 2026-22192) (Regulator). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#retatrutide-t2d-2026-10-28 retatrutide-t2d-2026-10-28 Wed, 28 Oct 2026 12:00:00 GMT pipeline In adults with type 2 diabetes not controlled on their current treatment, the company reports retatrutide lowered A1C and weight more than injectable semaglutide (Ozempic). These are the sponsor's first results, in one population; retatrutide is not approved. Lilly reported greater A1C reduction and weight loss with retatrutide than with the comparator, injectable semaglutide (Ozempic), in TRANSCEND-T2D-2, an open-label phase 3 trial in 1,298 adults with inadequately controlled type 2 diabetes. The figures are topline efficacy-estimand results. Gastrointestinal effects, dysesthesia and discontinuations were reported. Source: Eli Lilly release, 28 October 2026 (Sponsor release). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#zp9830-phase1-2026-10-19 zp9830-phase1-2026-10-19 Mon, 19 Oct 2026 12:00:00 GMT pipeline An early safety study in 32 healthy volunteers reported no serious or severe side effects over four weeks. That is early tolerability only: it says nothing yet about whether the drug helps people with autoimmune disease. Zealand reported results from the multiple ascending dose portion of a phase 1 trial involving 32 healthy participants over four weeks. No serious or severe adverse events were reported in this small study, which speaks to early tolerability only. A phase 1b study in psoriasis is underway; autoimmune efficacy has not been shown by these healthy-volunteer results. Source: Zealand Pharma release, 19 October 2026 (Sponsor release). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#import-alert-66-80 import-alert-66-80 Fri, 09 Oct 2026 12:00:00 GMT regulation The FDA can hold imported GLP-1 bulk ingredients at the border without examining each shipment, unless the maker and ingredient are on the alert's exception list. Import Alert 66-80 lets FDA field staff detain GLP-1 receptor agonist bulk drug substances without physical examination. Firms and ingredients that meet the alert's criteria are listed as exceptions on its green list, which the FDA launched on 5 September 2025. The current version, published 9 October 2026, updates the guidance on how a maker can be considered for the green list and adds orforglipron entries and new product codes. It is not a ban on every shipment. Source: FDA Import Alert 66-80 (published 9 October 2026); FDA press release, 5 September 2025 (Regulator). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#petrelintide-phase3 petrelintide-phase3 Tue, 22 Sep 2026 12:00:00 GMT pipeline An investigational amylin analogue, not a GLP-1, entered Phase 3. Starting Phase 3 is not an approval. Zealand Pharma, with partner Roche, announced on 22 September 2026 the start of the Phase 3a ZUPREME programme for once-weekly petrelintide versus placebo: three trials (ZUPREME-3, -4 and -5) in people with overweight or obesity without diabetes, with type 2 diabetes, and with established cardiovascular disease, about 7,000 participants in total. Petrelintide is investigational and not approved. Source: Zealand Pharma release, 22 September 2026 (Sponsor release). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#compounding-loophole compounding-loophole Mon, 31 Aug 2026 12:00:00 GMT regulation This is one person's argument, not a finding or a regulator's decision. An opinion column arguing that the shortage exception for compounding should end when a shortage ends, and that large-scale compounding should be directed toward medicines with fragile supply. It is the author's argument; it does not describe what any regulator has decided. Source: RealClearHealth (opinion), 31 August 2026 (Opinion). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#peptide-vendor-warning-letters peptide-vendor-warning-letters Mon, 24 Aug 2026 12:00:00 GMT regulation A warning letter goes to the seller and sets out what the FDA alleges. It is not a court finding, not a recall, and not a charge against anyone who bought. On 24 August 2026 the FDA's drug centre (CDER) issued warning letters to five online peptide sellers, alleging that products on their websites are unapproved new drugs and asking each to respond within 15 business days. The letters are the FDA's allegations, not an adjudication. Each letter is linked below. This site and the app never rank or link a seller. Source: FDA warning letters (CDER), 24 August 2026 (Regulator). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#mhra-orforglipron mhra-orforglipron Mon, 10 Aug 2026 12:00:00 GMT pipeline In the UK, orforglipron tablets are now authorised as a prescription-only medicine. The MHRA says it is not currently available through the NHS. On 10 August 2026 the MHRA authorised Eli Lilly's orforglipron (Foundayo) tablets for weight loss and weight maintenance in adults meeting set BMI criteria, alongside diet and physical activity, and for adults with insufficiently controlled type 2 diabetes. The MHRA describes it as prescription-only and states it is not currently available via the NHS; NHS use will follow processes including a NICE evaluation. Orforglipron is a small-molecule GLP-1 receptor agonist, not a peptide. Source: MHRA press release, 10 August 2026 (Regulator). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#stanford-compounded-glp1 stanford-compounded-glp1 Thu, 16 Jul 2026 12:00:00 GMT safety A university medical centre's explainer on why clinicians have safety concerns about compounded GLP-1 medicines. It is not a shop. A Stanford Medicine article dated 16 July 2026 in which clinicians explain how compounded versions of semaglutide and tirzepatide differ from FDA-approved products, why they have safety concerns, and what people taking one can do. Source: Stanford Medicine News Center, 16 July 2026 (University). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#retatrutide-triumph retatrutide-triumph Sat, 06 Jun 2026 12:00:00 GMT pipeline An investigational medicine reported Phase 3 results in obesity and in type 2 diabetes. It is not FDA-approved, and no approval elsewhere is listed in this item's sources. Eli Lilly announced TRIUMPH-1 topline results on 21 May 2026. On 6 June 2026, TRIUMPH-1 (obesity, 80 weeks) and TRANSCEND-T2D-1 (type 2 diabetes, 40 weeks) were presented at the American Diabetes Association's 86th Scientific Sessions, with TRANSCEND-T2D-1 published in The Lancet. Figures quoted in the release are sponsor-reported. Not FDA-approved, and no approval elsewhere is listed in this item's sources. Source: Eli Lilly press release, 6 June 2026 (Sponsor release). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#compounded-ae-reports compounded-ae-reports Sun, 31 May 2026 12:00:00 GMT safety A report means someone told the FDA about a problem while using the drug. It does not show the drug caused it, and the FDA says reports for compounded versions are likely underreported. As of 31 May 2026 the FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The FDA notes it is not always possible to tell whether the drug or other factors caused an event, and that because state-licensed pharmacies that are not outsourcing facilities are not required to report, events are likely underreported. Counts are not rates and do not measure risk. (Reporting cut-off 31 May 2026; FDA page content current as of 1 October 2026.) Source: FDA — concerns with unapproved GLP-1 drugs used for weight loss (Regulator). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#fda-503b-proposal fda-503b-proposal Fri, 01 May 2026 12:00:00 GMT regulation In the US, the FDA proposes that outsourcing facilities should not compound these three GLP-1s from bulk ingredients, finding no clinical need. It is a proposal, not a final decision. FDA proposed not to include the three substances on the 503B Bulks List, tentatively finding no clinical need for outsourcing facilities to compound them from bulk drug substances (Federal Register, 1 May 2026, 91 FR 23431, docket FDA-2018-N-3240). A notice of 26 June 2026 (91 FR 38719) extended the comment period to 30 July 2026; a final determination is pending. Source: Federal Register — 91 FR 23431, docket FDA-2018-N-3240 (Regulator). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#survodutide-synchronize survodutide-synchronize Tue, 28 Apr 2026 12:00:00 GMT pipeline An investigational medicine reported its first Phase 3 obesity results. It is not approved, and results from different trials cannot be compared directly. Boehringer Ingelheim reported SYNCHRONIZE-1 topline results on 28 April 2026: in adults with obesity or overweight without diabetes, mean weight loss at 76 weeks was up to 16.6% with survodutide versus 3.2% with placebo (efficacy estimand, 3.6 mg and 6.0 mg doses). The trial registry (NCT06066515) lists 726 participants enrolled. The full paper appears in NEJM (2026;395:776–787). Results from one trial cannot be compared directly with other trials. Survodutide is investigational and not approved. Source: Sponsor topline, 28 April 2026; NEJM 2026;395:776–787 (DOI 10.1056/NEJMoa2600751) (Journal). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#fda-compounder-clarification fda-compounder-clarification Wed, 01 Apr 2026 12:00:00 GMT regulation In the US, the shortages that gave compounders more room to make these drugs are over, and FDA's temporary enforcement discretion tied to them has ended. FDA lists the tirzepatide shortage as resolved on 19 December 2024 and the semaglutide shortage on 21 February 2025. Its enforcement discretion for 503B outsourcing facilities ended on 19 March 2025 (tirzepatide) and 22 May 2025 (semaglutide). 503A pharmacies remain limited from compounding drugs that are essentially copies of a commercially available drug. This describes US federal policy only (FDA page checked 25 October 2026). Source: FDA (page current as of 1 April 2026; checked 25 October 2026) (Regulator). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#orforglipron-us-approval orforglipron-us-approval Wed, 01 Apr 2026 12:00:00 GMT pipeline A once-daily tablet that is a small molecule rather than a peptide. Oral GLP-1 medicines already existed: oral semaglutide, a peptide tablet, was approved earlier. FDA approved NDA 220934 for Foundayo (orforglipron) tablets on 1 April 2026, for use with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction in adults with obesity, or with overweight and at least one weight-related condition. The FDA reports it as the first new molecular entity approved under its Commissioner's National Priority Voucher pilot. Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist. Source: FDA approval letter, NDA 220934 (1 April 2026) (Regulator). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#telehealth-warning-letters telehealth-warning-letters Tue, 03 Mar 2026 12:00:00 GMT regulation The FDA warned 30 telehealth companies about claims implying a compounded product is the same as an approved one. These are the FDA's allegations, not a court finding. The FDA announced 30 warning letters to telehealth companies over claims about compounded GLP-1 products, citing claims implying sameness with FDA-approved products and branding that obscures who compounded the drug. The FDA notes that compounded drugs are not FDA-approved and are not the same as generics, which are. Source: FDA press release, 3 March 2026 (Regulator). Educational and record keeping use only. Not medical advice. https://peptidelifestyle360.com/news#cagrisema-watch cagrisema-watch Thu, 18 Dec 2025 12:00:00 GMT pipeline The application is filed, not approved. The decision timing is the company's guidance; the FDA has not published a date. Novo Nordisk announced on 18 December 2025 that it had submitted a New Drug Application to the FDA for once-weekly CagriSema (cagrilintide and semaglutide) for chronic weight management. Novo's February 2026 release said an FDA decision is anticipated by late 2026. CagriSema is not approved; filed is not approved. Source: Novo Nordisk releases, 18 December 2025 and 23 February 2026 (Sponsor release). Educational and record keeping use only. Not medical advice.